- S&P 500 7,659.44 −1.09%
- Dow Jones 52,002.41 −0.34%
- Nasdaq 26,713.03 +0.08%
- VIX 19.99 +21.45%
- 10-year Treasury 5.09% −0.01
- Dollar index 121.40 −0.14%
- WTI crude $101.91 +1.04%
Biotech calendar: February 2027
Industry-sponsored phase 2 and phase 3 trials with an estimated primary completion in February 2027, from ClinicalTrials.gov.
Trial readouts
165 trials: 46 phase 3 (including phase 2/3) and 119 phase 2. Phase 3 first, then by date. Click a column to sort; type to filter.
| Primary completion | Sponsor | Drug | Condition | Phase | Status | Record |
|---|---|---|---|---|---|---|
| Feb 2027 | Alcon | Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preser…Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults | Ocular Hyperemia | Phase 3 | Recruiting | NCT07531043 |
| Feb 2027 | Celltrion | CT-P51, EU-approved KeytrudaA Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer | Non Squamous Non Small Cell Lung Cancer | Phase 3 | Active not recruiting | NCT06939595 |
| Feb 2027 | Celltrion | CT-P53, US-Ocrevus, EU-OcrevusA Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multip… | Relapsing-remitting Multiple Sclerosis | Phase 3 | Recruiting | NCT05906992 |
| Feb 2027 | Sino Biopharmaceutical Limited | TQC3721 Suspension for InhalationEvaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease | Phase 3 | Recruiting | NCT07464587 |
| Feb 2027 | Ems | DEH113Efficacy and Safety of DEH113 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea | Primary Dysmenorrhea | Phase 3 | Not yet recruiting | NCT06268054 |
| Feb 2027 | Eli Lilly and Company | OrforglipronA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | Obesity, Overweight | Phase 3 | Recruiting | NCT06672549 |
| Feb 2027 | Eurofarma Laboratorios S.A. | Experimental drugStudy of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris | Acne Vulgaris, Acne Vulgaris on the Face | Phase 3 | Recruiting | NCT06905210 |
| Feb 2027 | Fujian Shengdi Pharmaceutical Co., Ltd. | HRS9531Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin | Type 2 Diabetes | Phase 3 | Recruiting | NCT07060456 |
| Feb 2027 | Gilead Sciences | Sacituzumab Govitecan-hziy, Pembrolizumab, Paclitaxel and 3 moreStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously U… | Triple Negative Breast Cancer, PD-L1 Positive | Phase 3 | Active not recruiting | NCT05382286 |
| Feb 2027 | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | FRSW107Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment | Severe Hemophilia A | Phase 3 | Active not recruiting | NCT07663903 |
| Feb 2027 | Kallyope Inc. | ElismetrepA Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine | Migraine | Phase 3 | Recruiting | NCT07645924 |
| Feb 2027 | Keymed Biosciences Co.Ltd | StapokibatrtA Study of Stapokibatrt in Children Subjects With Atopic Dermatitis | Atopic Dermatitis | Phase 3 | Not yet recruiting | NCT07106372 |
| Feb 2027 | Kodiak Sciences Inc. | KSI-101, Sham ComparatorA Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (ME… | Macular Edema Secondary to Inflammation | Phase 3 | Recruiting | NCT06996080 |
| Feb 2027 | Otsuka Pharmaceutical | OPA-15406A Phase 3 Trial of OPA-15406 Foam in Children and Infants With Atopic Dermatitis | Atopic Dermatitis (AD) | Phase 3 | Not yet recruiting | NCT07184645 |
| Feb 2027 | PT Bio Farma | In-house Hepatitis B Vaccine, Registered Hepatitis B VaccineStudy Interchangeability Hep-B Vaccine Administered at Birth Dose | Vaccination Adverse Event, Immunogenicity, Vaccine | Phase 3 | Not yet recruiting | NCT07854847 |
| Feb 2027 | SK Life Science, Inc. | CarisbamateInvestigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults | Seizures, Lennox Gastaut Syndrome | Phase 3 | Recruiting | NCT05219617 |
| Feb 2027 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 610Efficacy and Safety Study of 610 in Patients With Severe Asthma | Asthma | Phase 3 | Recruiting | NCT06323213 |
| Feb 2027 | Trust Bio-sonics, Inc. | NH002 (Perflutren Lipid Microspheres) Injectable SuspensionSafety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac Echocardiography | Cardiac Diseases | Phase 3 | Active not recruiting | NCT06815627 |
| Feb 2, 2027 | Noema Pharma AG | BasimglurantAn Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia. | Trigeminal Neuralgia | Phase 2/3 | Active not recruiting | NCT05217628 |
| Feb 4, 2027 | Roche Holding | Ranibizumab, Port Delivery System with RanibizumabA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients … | Neovascular Age-related Macular Degeneration (nAMD) | Phase 3 | Active not recruiting | NCT04657289 |
| Feb 10, 2027 | Johnson & Johnson | IcotrokinraA Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Activ… | Arthritis, Psoriatic | Phase 3 | Recruiting | NCT06807424 |
| Feb 10, 2027 | Johnson & Johnson | Guselkumab Subcutaneous, Guselkumab IntravenousA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | Colitis, Ulcerative | Phase 3 | Active not recruiting | NCT06260163 |
| Feb 10, 2027 | Takeda Pharmaceutical Company | TeduglutideA Study of Teduglutide in Chinese Adults With Short Bowel Syndrome | Short Bowel Syndrome | Phase 3 | Active not recruiting | NCT06973304 |
| Feb 11, 2027 | Novartis | InclisiranEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | Acute Coronary Syndrome | Phase 3 | Recruiting | NCT07102628 |
| Feb 12, 2027 | Ocugen | Sub-Retinal Administration of OCU400-301A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa | Retinitis Pigmentosa | Phase 3 | Active not recruiting | NCT06388200 |
| Feb 13, 2027 | Epizyme, Inc. | Tazemetostat, Lenalidomide, RituximabA Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituxim… | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma and 1 more | Phase 3 | Active not recruiting | NCT04224493 |
| Feb 13, 2027 | SK Bioscience Co., Ltd. | NBP608 (Mid Potency), NBP608 (Low Potency), Varivax® and 1 moreSkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years | Varicella (Chickenpox) | Phase 3 | Recruiting | NCT07415252 |
| Feb 14, 2027 | Hudson Biotech | Tirzepatide, Reduced-calorie dietEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbi… | Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities | Phase 3 | Recruiting | NCT07481747 |
| Feb 15, 2027 | Acerta Pharma | Acalabrutinib, Bendamustine, RituximabA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | Lymphoma, Mantle Cell | Phase 3 | Active not recruiting | NCT02972840 |
| Feb 15, 2027 | CanSino Biologics | PCV13i, Prevnar 13A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Min… | Pneumococcal Infections, Streptococcal Infections and 1 more | Phase 3 | Active not recruiting | NCT07017777 |
| Feb 15, 2027 | Moderna | mRNA-1403A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis | Acute Gastroenteritis, Norovirus Acute Gastroenteritis | Phase 3 | Active not recruiting | NCT06592794 |
| Feb 16, 2027 | Bristol-Myers Squibb | Repotrectinib, CrizotinibA Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-po… | Carcinoma, Non-Small-Cell Lung | Phase 3 | Active not recruiting | NCT06140836 |
| Feb 16, 2027 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg and 1 moreA Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus | Type 2 Diabetes | Phase 3 | Recruiting | NCT07082114 |
| Feb 17, 2027 | Sanofi | Itepekimab (SAR440340)An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chr… | Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Active not recruiting | NCT07424144 |
| Feb 18, 2027 | AstraZeneca | Zibotentan/Dapagliflozin, DapagliflozinStudy to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic K… | Chronic Kidney Disease With High Proteinuria | Phase 3 | Active not recruiting | NCT06087835 |
| Feb 19, 2027 | Xuanzhu Biopharmaceutical Co., Ltd. | Anaprazole Sodium enteric-coated tablet, Esomeprazole magnesium enteric-coated tabletsThe Clinical Trail to Evaluate the Efficacy and Safety of Anaprazole Sodium Enteric-coated Tablets Combined With Bismuth-containing Quadrupl… | HELICOBACTER PYLORI INFECTIONS | Phase 3 | Not yet recruiting | NCT07606833 |
| Feb 20, 2027 | Regeneron Pharmaceuticals | REGN7508, Apixaban, EnoxaparinREGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults | Venous Thromboembolism (VTE) | Phase 3 | Recruiting | NCT07015905 |
| Feb 22, 2027 | Acerta Pharma | acalabrutinib, Prednisone, Rituximab and 3 moreA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | Diffuse Large B-Cell Lymphoma | Phase 3 | Active not recruiting | NCT04529772 |
| Feb 22, 2027 | AstraZeneca | OsimertinibRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T) | Cancer | Phase 3 | Active not recruiting | NCT05629234 |
| Feb 22, 2027 | Novartis | Remibrutinib, DupilumabA Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequa… | Chronic Spontaneous Urticaria (CSU) | Phase 3 | Active not recruiting | NCT06868212 |
| Feb 23, 2027 | AstraZeneca | AnifrolumabPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | Lupus Nephritis | Phase 3 | Active not recruiting | NCT05138133 |
| Feb 25, 2027 | GSK | HFA-152a, HFA-134aA Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroetha… | Asthma | Phase 3 | Recruiting | NCT07645248 |
| Feb 26, 2027 | Ardelyx | Tenapanor 5 mg BID, Tenapanor 25 mg BID, Tenapanor 50 mg BIDA 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults | Chronic Idiopathic Constipation (CIC) | Phase 3 | Recruiting | NCT07382167 |
| Feb 26, 2027 | Novartis | Alpelisib, Trastuzumab, PertuzumabStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Br… | Advanced HER2+Breast Cancer | Phase 3 | Active not recruiting | NCT04208178 |
| Feb 28, 2027 | Innovent Biologics | Aflibercept Ophthalmic, IBI302A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD | Neovascular Age-related Macular Degeneration | Phase 3 | Active not recruiting | NCT05972473 |
| Feb 28, 2027 | Institut Pasteur | –Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients | Hidradenitis Suppurativa | Phase 3 | Recruiting | NCT05821478 |
| Feb 2027 | 60 Degrees Pharmaceuticals, INC. | Tafenoquine 100mgB-FREE Chronic Babesiosis Study | Chronic Babesiosis | Phase 2 | Recruiting | NCT06656351 |
| Feb 2027 | AbCellera Biologics Inc. | ABCL635Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause | Vasomotor Symptoms Associated With Menopause, Healthy Volunteers | Phase 1/2 | Active not recruiting | NCT07118891 |
| Feb 2027 | AbbVie | Mirvetuximab Soravtansine, Lubricating Eye Drops, Prednisolone acetate ophthalmic suspension 1% eye drops and 1 moreA Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian … | Recurrent Ovarian Cancer, Folate Receptor-Alpha Positive | Phase 2 | Active not recruiting | NCT06365853 |
| Feb 2027 | AbbVie | LutikizumabA Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic… | Hidradenitis Suppurativa, Atopic Dermatitis | Phase 2 | Recruiting | NCT06524635 |
| Feb 2027 | AbbVie | Lutikizumab, RavagalimabA Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | Phase 2 | Recruiting | NCT06972446 |
| Feb 2027 | AbbVie | Azacitidine, IMGN632, VenetoclaxIMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia | Acute Myeloid Leukemia | Phase 1/2 | Active not recruiting | NCT04086264 |
| Feb 2027 | Almirall, S.A. | LAD328A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa | Hidradenitis Suppurativa | Phase 2 | Recruiting | NCT07547813 |
| Feb 2027 | Antag Therapeutics | AT673 low dose, AT673 high doseA Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes… | Adults With Overweight/Obesity and Type 2 Diabetes | Phase 2 | Active not recruiting | NCT07724340 |
| Feb 2027 | Arrowhead Pharmaceuticals | ARO-ALK7A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus | Obesity, Diabetes Mellitus, Type 2 | Phase 1/2 | Recruiting | NCT06937203 |
| Feb 2027 | Bausch & Lomb | BL1107BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial | Dry Eye Disease | Phase 2 | Not yet recruiting | NCT07778888 |
| Feb 2027 | Bausch & Lomb | Topical Ocular BL1332 low dose, Topical Ocular BL1332 high dose, BL1332 Vehicle ophthalmic vehicleA Study to Evaluate the Use of Topical Ocular BL1332 for the Management of Postoperative Ocular Pain Following Photorefractive Keratectomy | Pain, Postoperative | Phase 2 | Not yet recruiting | NCT07412496 |
| Feb 2027 | Bavarian Nordic | MVA-BN-WEVA Phase 2 Trial in Healthy Adult Participants of the Recombinant MVA-BN-WEV Vaccine | Encephalitis | Phase 2 | Active not recruiting | NCT06899802 |
| Feb 2027 | Bond Biosciences | BBI-001A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary Hemochromatosis | Hereditary Hemochromatosis | Phase 1/2 | Recruiting | NCT07371793 |
| Feb 2027 | Candel Therapeutics | aglatimagene besadenovec + valacyclovir, External Beam Radiation Therapy (EBRT)A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec | Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma) | Phase 2 | Recruiting | NCT07332000 |
| Feb 2027 | Sino Biopharmaceutical Limited | TQB6411 InjectionClinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer | Esophageal Cancer | Phase 1/2 | Recruiting | NCT07367516 |
| Feb 2027 | Clarent Biopharma, Inc. | CBP-0276 capsules 100mgOral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA) | Arthritic Psoriasis | Phase 2 | Not yet recruiting | NCT07706530 |
| Feb 2027 | Day One Biopharmaceuticals, Inc. | Emi-LeA Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors | Triple Negative Breast Cancer, Breast Cancer and 5 more | Phase 1/2 | Recruiting | NCT05377996 |
| Feb 2027 | Disc Medicine, Inc. | DISC-3405A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) | Polycythemia Vera (PV) | Phase 2 | Active not recruiting | NCT06985147 |
| Feb 2027 | DualityBio Inc. | DB-1419First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors | Solid Tumor, Adult | Phase 1/2 | Recruiting | NCT06554795 |
| Feb 2027 | Eli Lilly and Company | BrenipatideA Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse | Smoking | Phase 2 | Recruiting | NCT07223840 |
| Feb 2027 | Eli Lilly and Company | Abemaciclib, TemozolomideA Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Ra… | Glioma | Phase 2 | Active not recruiting | NCT06413706 |
| Feb 2027 | Enlivex | AllocetraIntra-Articular Allocetra in Patients With Primary Knee Osteoarthritis | Primary Knee Osteoarthritis | Phase 2 | Recruiting | NCT07580716 |
| Feb 2027 | GI Innovation | GI-108A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Advanced Solid Tumor, Metastatic Solid Tumor and 4 more | Phase 1/2 | Recruiting | NCT07172802 |
| Feb 2027 | Genelux Corporation | Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel fo… and 2 moreEfficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxe… | Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma and 6 more | Phase 2 | Recruiting | NCT06463665 |
| Feb 2027 | Jiangsu Hengrui Medicine | FH-006 for Injection, SHR-1316 Injection, Paclitaxel for Injection (Albumin-Bound)A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors | Malignant Solid Tumor | Phase 1/2 | Recruiting | NCT07136142 |
| Feb 2027 | Krystal Biotech, Inc. | KB707, Pembrolizumab (KEYTRUDA®), Chemotherapy and 1 moreA Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | Lung Cancer, Non-small Cell, Lung Cancer Metastatic and 3 more | Phase 1/2 | Recruiting | NCT06228326 |
| Feb 2027 | Liquidia Technologies, Inc. | LIQ861 (treprostinil) inhalation powder - Dose Titration Arm, LIQ861 (treprostinil) inhalation powder - fixed dose armA Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks | Raynaud's Phenomenon Secondary to Systemic Sclerosis | Phase 2 | Not yet recruiting | NCT07748000 |
| Feb 2027 | MediLink Therapeutics (Suzhou) Co., Ltd. | YL201 for InjectionA Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 2 | Recruiting | NCT06241846 |
| Feb 2027 | Neurocrine Biosciences | NBI-1065890Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia | Tardive Dyskinesia | Phase 2 | Recruiting | NCT07365462 |
| Feb 2027 | Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd. | 0.4% ZOC2017217, ControlA Multicenter, Randomized, Double-Masked, Placebo-Controlled Pilot Study to Evaluate the Efficacy and Safety of ZOC2017217 in Subjects With … | Age Related Cataracts | Phase 2 | Active not recruiting | NCT07395986 |
| Feb 2027 | Prevail Therapeutics | LY3884961, Methylprednisolone, Sirolimus and 1 morePhase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE) | Gaucher Disease, Type 2 | Phase 1/2 | Active not recruiting | NCT04411654 |
| Feb 2027 | Qilu Pharmaceutical Co., Ltd. | QLC1401A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer | Advanced Breast Cancer | Phase 1/2 | Not yet recruiting | NCT07173556 |
| Feb 2027 | RDC Clinical Pty Ltd | Lavender Oil, Palmitoylethanolamide (PEA), OleoylethanolamideSleep and Stress Study | Sleep Disorder (Disorder), Stress and 1 more | Phase 2 | Recruiting | NCT07315516 |
| Feb 2027 | RIGImmune Inc. | RIG-101RIG 101 Trial in Healthy Adults and Adults With Asthma | Healthy Adult Participants, Asthma Exacerbation and 1 more | Phase 1/2 | Recruiting | NCT07488897 |
| Feb 2027 | Rivus Pharmaceuticals, Inc. | HU6A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associat… | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Phase 2 | Recruiting | NCT07491458 |
| Feb 2027 | Sanaria Inc. | Genetically attenuated PfSPZ Vaccine, Normal Saline (0.9% Sodium Chloride)Field Trial of PfSPZ-LARC2 Vaccine in Burkinabe Adults | Malaria (Plasmodium Falciparum) | Phase 2 | Recruiting | NCT07385287 |
| Feb 2027 | Shandong New Time Pharmaceutical Co., LTD | Vonorasan fumarate injection1, Vonorasan fumarate injection2, Esomeprazole sodium for injectionPhase II Clinical Study of Vonorasan Fumarate Injection in the Treatment of Peptic Ulcer Bleeding | Peptic Ulcer Bleeding | Phase 2 | Not yet recruiting | NCT06783257 |
| Feb 2027 | Jiangsu Hengrui Medicine | HRS-5346Study of Oral HRS-5346 in Adult Patients With Elevated Lipoprotein(a) and High Risk of Cardiovascular Events | Lipoprotein Disorder | Phase 2 | Not yet recruiting | NCT07767513 |
| Feb 2027 | Shanghai RAAS Blood Products Co., Ltd. | SR604A Phase II Exploratory Study of SR604 Injection Evaluating the Safety and Efficacy in the Treatment of Congenital Coagulation Factor VII Def… | Factor VII Deficiency | Phase 2 | Not yet recruiting | NCT07711158 |
| Feb 2027 | Sovargen | SVG103Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (T… | Focal Cortical Dysplasia, Tuberous Sclerosis Complex (TSC) and 1 more | Phase 1/2 | Recruiting | NCT07287202 |
| Feb 2027 | SparingVision | SPVN06Promising ROd-cone DYstrophy Gene therapY | Retinitis Pigmentosa | Phase 1/2 | Active not recruiting | NCT05748873 |
| Feb 2027 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 610A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma | Asthma | Phase 2 | Active not recruiting | NCT06680947 |
| Feb 2027 | Suzhou HepaThera Biotech Co., Ltd. | HT-101, HT-102A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection | Chronic Hepatitis B | Phase 2 | Active not recruiting | NCT07245953 |
| Feb 2027 | TearSolutions, Inc. | LacripepA Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep in Subjects… | Neurotrophic Keratitis | Phase 2 | Recruiting | NCT07568730 |
| Feb 1, 2027 | AB Biotics, SA | Lactiplantibacillus plantarum Probiotic MixtureInvestigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechani… | MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Fatty Liver Disease, Nonalcoholic and 1 more | Phase 2 | Recruiting | NCT07193927 |
| Feb 1, 2027 | Amplia Therapeutics Limited | AMP945 ascending doses, AMP945 RP2DACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer | Pancreatic Cancer, PDAC and 1 more | Phase 1/2 | Active not recruiting | NCT05355298 |
| Feb 1, 2027 | Boryung Pharmaceutical Co., Ltd | BR1400-1, BR1400-2, BR1400-3 and 5 moreA Study of BR1400-1, BR1400-2, BR1400-3, BR1400-4, and BR1400-5 in Patients With Essential Hypertension | Essential Hypertension | Phase 2 | Not yet recruiting | NCT07373613 |
| Feb 1, 2027 | Gracell Biotechnologies Inc. | GC012F InjectionA Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus | Refractory Systemic Lupus Erythematosus | Phase 1/2 | Active not recruiting | NCT06530849 |
| Feb 1, 2027 | Novartis | LEE011Ribociclib (LEE011) Rollover Study for Continued Access | Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies | Phase 2 | Active not recruiting | NCT02934568 |
| Feb 1, 2027 | Tvardi Therapeutics, Inc. | TTI-101, Pembrolizumab, Atezolizumab and 1 moreA Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Ca… | Hepatocellular Carcinoma | Phase 1/2 | Recruiting | NCT05440708 |
| Feb 2, 2027 | Cellvax Therapeutics Inc | FK-PC101FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer | Prostate Cancer (Adenocarcinoma), Prostate CA and 5 more | Phase 2 | Recruiting | NCT06636682 |
| Feb 2, 2027 | Novartis | LXH254, LTT462, Trametinib and 1 moreStudy of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | Melanoma | Phase 2 | Active not recruiting | NCT04417621 |
| Feb 2, 2027 | Vertex Pharmaceuticals | VX-670A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | Myotonic Dystrophy Type 1 (DM1) | Phase 1/2 | Active not recruiting | NCT06185764 |
| Feb 3, 2027 | InventVacc Biologicals Inc. | Haemophilus influenzae serotype a vaccine candidatePhase 2 Trial of a Haemophilus Influenzae Serotype a (Hia) Glycoconjugate Vaccine | Haemophilus Influenzae, Haemophilus Influenzae Type a | Phase 2 | Active not recruiting | NCT07743008 |
| Feb 4, 2027 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | HDM1005 dose level 1, HDM1005 dose level 2, HDM1005 dose level 3 and 1 moreEfficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes | Obesity | Phase 2 | Recruiting | NCT07521631 |
| Feb 4, 2027 | Novartis | KAE609, SoC (Coartem), KLU156Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria … | Uncomplicated Plasmodium Falciparum Malaria | Phase 2 | Recruiting | NCT07811908 |
| Feb 5, 2027 | Applied Biology, Inc. | DA-020, DA-020 and HyperforinClinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia | Chemotherapy Induced Alopecia, Chemotherapy Side Effects | Phase 1/2 | Recruiting | NCT07397325 |
| Feb 5, 2027 | Bristol-Myers Squibb | Nivolumab, Ipilimumab, Carboplatin and 3 moreA Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participant… | Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | NCT06946797 |
| Feb 5, 2027 | EktaH | Investigational product is a modified linoleic acid, named…A PHASE 2A, EXPLORATORY, RANDOMIZED, SINGLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY OF WEIGHT LOSS INDUCED BY NKS-3 IN OBES… | Obesity / Overweight, Obesity (BMI Equal to or >30) | Phase 2 | Not yet recruiting | NCT07882654 |
| Feb 7, 2027 | Intra-IMMUSG Pte Ltd | PRL3-ZUMAB, Normal Saline (0.9% Sodium Chloride)A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD) | Neovascular Age Related Macular Degeneration | Phase 1/2 | Recruiting | NCT07547228 |
| Feb 8, 2027 | Abcentra | OrticumabFocused Orticumab Research for Treating Inflammation in Coronary Arteries | Acute Coronary Syndromes, Coronary Arterial Disease (CAD) and 4 more | Phase 2 | Recruiting | NCT06927739 |
| Feb 9, 2027 | Aston Sci. Inc. | AST-301, rhuGM-CSFTherapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer | Gastric Cancer | Phase 2 | Active not recruiting | NCT05771584 |
| Feb 9, 2027 | Regeneron Pharmaceuticals | REGN7508, REGN9933, ApixabanSafety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation | Atrial Fibrillation (AF) | Phase 2 | Recruiting | NCT07175428 |
| Feb 9, 2027 | Sanofi | BrivekimigBrivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa | Hidradenitis Suppurativa | Phase 2 | Recruiting | NCT07170917 |
| Feb 10, 2027 | AstraZeneca | Trastuzumab deruxtecan, BevacizumabA Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors | Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer) | Phase 2 | Active not recruiting | NCT06271837 |
| Feb 10, 2027 | Shanghai Henlius Biotech | HLX53 (1000mg), HLX53 (2000mg), HLX10 and 1 moreA Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untr… | Carcinoma, Hepatocellular | Phase 2 | Recruiting | NCT06349980 |
| Feb 11, 2027 | AstraZeneca | AZD4144A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. | Sepsis, Acute Kidney Injury | Phase 2 | Recruiting | NCT07215702 |
| Feb 11, 2027 | Gan & Lee Pharmaceuticals Co., Ltd. | GZR101-80, GZR33 or Insulin degludec/Insulin aspart or Insulin aspart…Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes | Type 2 Diabetes (T2DM) | Phase 2 | Not yet recruiting | NCT07387003 |
| Feb 11, 2027 | Sanofi | Rilzabrutinib dose 1, Rilzabrutinib dose 2A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease | Graves' Disease | Phase 2 | Recruiting | NCT06984627 |
| Feb 12, 2027 | Jecho Biopharmaceuticals Co., Ltd. | JL18008 20 μg/kg, JL18008 40 μg/kg, JL18008 70 μg/kgA Study to Evaluate JL18008 in Subject With HIV Immunological Non-Responders | HIV Infections | Phase 1/2 | Recruiting | NCT07579741 |
| Feb 12, 2027 | Merck & Co. | pembrolizumab, doxorubicin, vinblastine and 7 moreSafety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) | Hodgkin Lymphoma | Phase 2 | Active not recruiting | NCT03407144 |
| Feb 14, 2027 | Beijing Biotech | EB-NK-301, FludarabinePhase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors | Advanced Solid Tumors, Metastatic Solid Tumors and 1 more | Phase 1/2 | Recruiting | NCT07589530 |
| Feb 14, 2027 | Beijing Biotech | EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1), EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1), Lymphodepleting chemotherapy (Flu/Cy)Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma | Pancreatic Ductal Adenocarcinoma (PDAC), Unresectable Locally Advanced or Metastatic Disease | Phase 1/2 | Recruiting | NCT07480928 |
| Feb 14, 2027 | Beijing Biotech | EB-DART-NK01 (DLL3/CD56 CAR-NK cells), Lymphodepleting chemotherapyAdaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) | Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC and 1 more | Phase 1/2 | Recruiting | NCT07480213 |
| Feb 14, 2027 | Beijing Biotech | EB-DART-NK01, Lymphodepleting chemotherapyAdaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) | Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC and 1 more | Phase 1/2 | Recruiting | NCT07744256 |
| Feb 14, 2027 | Beijing Biotech | Dual-target CAR-NK cells (EB-DT-CAR-NK), Lymphodepleting chemotherapy, Supportive careDual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) | Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer and 1 more | Phase 1/2 | Recruiting | NCT07486089 |
| Feb 14, 2027 | Beijing Biotech | Dual-target CAR-NK cells, Lymphodepleting chemotherapy, Supportive CareDual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC | Non-Small Cell Lung Cancer, Advanced/Metastatic NSCLC | Phase 1/2 | Recruiting | NCT07467863 |
| Feb 14, 2027 | Eisai | E2086A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy | Narcolepsy | Phase 2 | Recruiting | NCT07493265 |
| Feb 14, 2027 | Evopoint Biosciences Inc. | XNW29016A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment | Tumor, Solid | Phase 1/2 | Recruiting | NCT06987500 |
| Feb 14, 2027 | Hudson Biotech | MOTS-c (MDP), Route Subcutaneous injection, RegimenMOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity | Prediabetes, Insulin Resistance and 1 more | Phase 2 | Recruiting | NCT07505745 |
| Feb 14, 2027 | Hudson Biotech | Pentadecapeptide BPC 157BPC 157 for Acute Hamstring Muscle Strain Repair | Hamstring Muscle Strain, Skeletal Muscle Injury | Phase 2 | Recruiting | NCT07437547 |
| Feb 14, 2027 | Hudson Biotech | TB-500TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD | Atherosclerotic Cardiovascular Diseases, Endothelial Dysfunction | Phase 1/2 | Recruiting | NCT07487363 |
| Feb 14, 2027 | Hudson Biotech | GHK-Cu Gel (Copper(II)-peptide complex)Topical GHK-Cu Gel for Acute Skin Wound Healing | Acute Standardized Cutaneous Wounds (Punch-biopsy Wounds) | Phase 2 | Recruiting | NCT07437586 |
| Feb 14, 2027 | Hudson Biotech | Tesamorelin, Standardized lifestyle counselingTesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) | Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis and 1 more | Phase 2 | Recruiting | NCT07481734 |
| Feb 14, 2027 | Hudson Biotech | Melanotan II (MT-II), Narrowband UV-B (NB-UVB) phototherapyMelanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo | NonSegmental Vitiligo, Nonsegmental Vitiligo (Stable) | Phase 2 | Recruiting | NCT07437560 |
| Feb 15, 2027 | Ikaria Bioscience Pty Ltd | RN3161, TirzepatidePhase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy… | Obesity &Amp; Overweight | Phase 1/2 | Recruiting | NCT07245771 |
| Feb 17, 2027 | Beijing Biotech | Dual-target CAR-NK cell product, Lymphodepleting chemotherapy, Standard supportive careDual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) | Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma and 2 more | Phase 1/2 | Recruiting | NCT07480954 |
| Feb 17, 2027 | Merck & Co. | TulisokibartStudy to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015) | Psoriatic Arthritis | Phase 2 | Active not recruiting | NCT07486960 |
| Feb 17, 2027 | Takeda Pharmaceutical Company | TAK-279A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Croh… | Crohn's Disease | Phase 2 | Recruiting | NCT06233461 |
| Feb 20, 2027 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | SKB518, Tislelizumab, CarboplatinA Study of SKB518 in Patients With Lung Cancer | Lung Carcinoma | Phase 2 | Recruiting | NCT07019675 |
| Feb 22, 2027 | Jiangsu vcare pharmaceutical technology co., LTD | VC005 groupA Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adul… | Atopic Dermatitis | Phase 2 | Recruiting | NCT07598383 |
| Feb 25, 2027 | GE HealthCare | GE-287, VizamylFlutemetamol F 18 Injection Formulation Comparison | Cognitive Dysfunction | Phase 2 | Not yet recruiting | NCT07873463 |
| Feb 26, 2027 | Roche Holding | Cevostamab, TocilizumabA Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refrac… | Multiple Myeloma | Phase 1/2 | Active not recruiting | NCT05535244 |
| Feb 26, 2027 | Johnson & Johnson | JNJ-68284528, Lenalidomide, Daratumumab and 2 moreA Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participant… | Multiple Myeloma | Phase 2 | Active not recruiting | NCT04133636 |
| Feb 26, 2027 | Johnson & Johnson | BleximenibA Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) | Acute Leukemia | Phase 1/2 | Recruiting | NCT04811560 |
| Feb 26, 2027 | NS Pharma, Inc. | NS-089/NCNP-02NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD) | Duchenne Muscular Dystrophy, Exon 44 and 1 more | Phase 2 | Active not recruiting | NCT05996003 |
| Feb 26, 2027 | Novartis | Alpelisib, FulvestrantStudy Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced … | Advanced Breast Cancer | Phase 2 | Active not recruiting | NCT04524000 |
| Feb 26, 2027 | Novartis | LEE011, Letrozole, BYL719Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer | Breast Cancer | Phase 1/2 | Active not recruiting | NCT01872260 |
| Feb 26, 2027 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Belzutifan, CabozantinibA Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-0… | Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC) and 7 more | Phase 2 | Active not recruiting | NCT03634540 |
| Feb 26, 2027 | Pfizer | PF-07220060 + PF-07104091 combination dose escalation, PF-07104091 + PF-07220060 + fulvestrant dose expansion, PF-07104091 + PF-07220060 + letrozole dose expansionA Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid … | Breast Cancer, Solid Tumors | Phase 1/2 | Active not recruiting | NCT05262400 |
| Feb 26, 2027 | Risen (Suzhou) Pharma Tech Co., Ltd. | JS105, Fulvestrant injection, Dalpiciclib Isetionate Tablets and 5 moreA Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors | Advanced Solid Tumors | Phase 1/2 | Recruiting | NCT06208410 |
| Feb 27, 2027 | Hangzhou Sciwind Biosciences Co., Ltd. | XW003 injection, semaglutide injectionA Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH) | Obesity, Weight Management | Phase 2 | Active not recruiting | NCT07073417 |
| Feb 28, 2027 | Akeso | VG2025, AK112A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases | Colorectal Cancer With Hepatic Metastases | Phase 1/2 | Not yet recruiting | NCT07357220 |
| Feb 28, 2027 | Aulos Bioscience, Inc. | AU-007, Aldesleukin, Avelumab and 1 moreStudy of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Met… | Advanced Solid Tumor, Metastatic Cancer and 2 more | Phase 1/2 | Recruiting | NCT05267626 |
| Feb 28, 2027 | Bluefin Biomedicine, Inc. | BFB759A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis | Atopic Dermatitis (AD) | Phase 2 | Active not recruiting | NCT07105488 |
| Feb 28, 2027 | BrightGene Bio-Medical Technology Co. | BGM0504 tabletsA Study to Evaluate Efficacy and Safety of BGM0504 Tablets in Overweight or Obese Participants Without Diabetes | Overweight or Obese Participants Without Diabetes | Phase 2 | Recruiting | NCT07658560 |
| Feb 28, 2027 | Elpiscience (Suzhou) Biopharma, Ltd. | ES102, ToripalimabA Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer | Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | NCT06623136 |
| Feb 28, 2027 | Forte Biosciences, Inc. | FB102Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease | Celiac Disease | Phase 2 | Recruiting | NCT06982963 |
| Feb 28, 2027 | Hansa Biopharma | ImlifidaseImlifidase Prior to Kidney Transplant in Highly Sensitised Children | Kidney Transplantation in Highly Sensitized Patients | Phase 2 | Recruiting | NCT05753930 |
| Feb 28, 2027 | Jemincare | JMKX003142 will be administered orally, PlcaceboTrial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) | ADPKD (Autosomal Dominant Polycystic Kidney Disease) | Phase 2 | Recruiting | NCT06800651 |
| Feb 28, 2027 | Hansoh Pharmaceutical Group | HS-20118A Phase 2 Study of HS-20118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-Severe Plaque Psoriasis | Moderate to Severe Plaque Psoriasis | Phase 2 | Not yet recruiting | NCT07765628 |
| Feb 28, 2027 | Longbio Pharma | LP-003 InjectionA Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | Phase 2 | Not yet recruiting | NCT07313917 |
| Feb 28, 2027 | Neonc Technologies Holdings, INC. | NEO212 Oral Capsule, Ipilimumab, Pembrolizumab and 6 moreSafety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype and 19 more | Phase 1/2 | Recruiting | NCT06047379 |
| Feb 28, 2027 | NovaOnco Therapeutics Co., Ltd. | XS-02 capsulesA Study of XS-02 Capsules in Patients With Advanced Solid Tumors | Solid Tumor, Ovarian Cancer and 2 more | Phase 1/2 | Not yet recruiting | NCT06531486 |
| Feb 28, 2027 | Polaris Group | ADI-PEG 20, TemozolomideADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme | Glioblastoma Multiforme (GBM) | Phase 2 | Active not recruiting | NCT04587830 |
| Feb 28, 2027 | R1 Therapeutics | AP306 75 mg BID, AP306 125 mg BID, AP306 150 mg BID and 3 moreA Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia | Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis and 1 more | Phase 2 | Recruiting | NCT06712654 |
| Feb 28, 2027 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | FXS5626 tabletA Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU | Active Non-anterior, Non-infectious Uveitis | Phase 2 | Recruiting | NCT07552012 |
| Feb 28, 2027 | Shanghai Institute Of Biological Products | MVA-SIBP low dose, MVA-SIBP high dose, MVA-BNEvaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo | Monkeypox (Mpox) | Phase 2 | Not yet recruiting | NCT07253675 |
| Feb 28, 2027 | T3 Pharmaceuticals AG | Pembrolizumab+T3P-Y058-739, T3P-Y058-739 (IV), T3P-Y058-739 (IT)First in Human Study of T3P-Y058-739 (T3P) | Advanced Solid Tumor | Phase 1/2 | Recruiting | NCT05120596 |
Trials: ClinicalTrials.gov, the U.S. National Library of Medicine’s registry, industry-sponsored studies only. Completion dates are the sponsor’s own estimates and often slip. Advisory committees: the FDA advisory committee calendar. A trial’s primary completion is when its main measurement is done; companies usually report top-line results weeks to months later, and not always. FDA decision dates (PDUFA goal dates) are not here: the FDA does not publish them, and companies announce them only in their own press releases.